These findings also suggested that TNF-α inhibitors or upregulations of miR-181c expression may be a potential therapeutic target to preserve beta cell mass, at least in part, for the treatment of type 1 and type 2 diabetes and much further studies will be needed to apply clinical application. The gene discussed is TNF; the disease is type 2 diabetes mellitus.